RenovoRx Forms Medical Advisory Board to Support RenovoCath
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy RNXT?
RenovoRx announced the formation of a RenovoCath Medical Advisory Board, MAB, to support its clinical and strategic initiatives. "The formation of the MAB marks an exciting milestone for RenovoRx, and we're honored to have such respected interventional radiology experts supporting advancement of the RenovoCath device," said Ramtin Agah, MD, RenovoRx's Chairman and Chief Medical Officer. "Their collective expertise will help guide real-world evidence generation as we advance our novel approach to localized, targeted drug delivery, aiming to improve outcomes for patients diagnosed with difficult-to-treat cancers."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.882
Low
3.00
Averages
5.63
High
12.50
Current: 0.882
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RenovoRx Expands RenovoCath Adoption Across U.S. Cancer Centers
- Significant Commercial Progress: RenovoRx announced that 12 U.S. cancer centers are now utilizing the RenovoCath device, marking a substantial increase from previous figures and indicating strong market demand for the product.
- Growing Clinical Demand: With RenovoCath being integrated into overall cancer treatment paradigms, 33 centers have requested access to the device, tripling the number of centers since the first quarter, reflecting clinical recognition and demand.
- Sales Pipeline Expansion: RenovoRx's sales pipeline has significantly expanded since the first quarter of 2025, with the increase in potential commercial centers laying the groundwork for substantial revenue growth expected in 2026.
- Strategic Implications: The widespread adoption of RenovoCath not only enhances the company's market position in cancer treatment but also provides crucial support for future clinical research and product development, further solidifying its leadership in the industry.
See More
RenovoRx Expands Market for Cancer Treatment Device
- Market Demand Growth: Over the past year, the number of U.S. cancer centers utilizing RenovoRx's FDA-cleared device, RenovoCath, has increased to 12, indicating a rising clinical demand that is expected to drive revenue growth in 2026.
- Procedure Success Rate: Since receiving FDA clearance in 2014, RenovoCath has successfully completed over 700 procedures, reflecting strong physician satisfaction and an increase in repeat orders, further solidifying its market position.
- Executive Appointment Strengthens Strategy: The company appointed founder Dr. Ramtin Agah as Executive Chairman to leverage his medical background in driving market penetration and clinical adoption of RenovoCath, enhancing the execution of the company's commercial strategy.
- Sales Team Launch: RenovoRx's sales and marketing team, launched in late 2025, has begun promoting the adoption of the TAMP therapy platform, which is expected to further expand the customer base and increase market share.
See More
RenovoRx Clinical Data Abstract Accepted for Presentation at SIR 2026
- Clinical Data Abstract Accepted: RenovoRx announced that its clinical data abstract submitted for the 2026 Society of Interventional Radiology Annual Meeting has been accepted, showcasing the potential of its TAMP therapy platform for pancreatic cancer, which is expected to enhance the company's reputation in oncology treatment.
- Multidisciplinary Team Involvement: The abstract was submitted by a multidisciplinary team of experts from Moffitt Cancer Center, highlighting the involvement of Dr. Mustafa Al-Roubaie, a member of RenovoRx's Medical Advisory Board, indicating the company's influence and collaborative capabilities in the field.
- Innovative Treatment Mechanism: The abstract explores the hypothesis of local chemotherapy delivery via RenovoRx's patented TAMP platform to address the common issue of poor vascularity in pancreatic cancer patients, potentially improving treatment efficacy and offering new hope for patients.
- Future Outlook: The presentation of this abstract is scheduled for April 13, 2026, which is expected to attract industry attention, further driving RenovoRx's market promotion and product development, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Investor Focus: When considering buying Micron Technology (MU) stock, analysts' opinions are particularly crucial, and investors should pay attention to these rating changes to make informed investment choices.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a thorough market insight.
- Market Impact: Adjustments in analysts' ratings not only affect the performance of individual stocks but may also create fluctuations in overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
RenovoRx Forms Medical Advisory Board to Enhance Oncology Strategies
- Formation of Medical Advisory Board: RenovoRx has established a dedicated Medical Advisory Board for RenovoCath, bringing together leading US interventional radiology experts to support clinical and strategic initiatives, thereby advancing the TAMP therapy platform in clinical indications with high unmet medical needs.
- Support for Clinical Trials: The MAB will provide critical insights into RenovoRx's clinical and market strategies, particularly in investigator-initiated trials supported by the company, which are designed to generate meaningful data that may broaden the application of the TAMP platform.
- Market Advancement of Product: With FDA clearance for the RenovoCath device, which enables targeted drug delivery across the arterial wall near tumors, the MAB's feedback will assist the sales and marketing team in bringing RenovoCath to market as a standalone device, enhancing its competitive position.
- Expert Team Composition: Initial members include experienced interventional radiologists such as Dr. Nadine Abi-Jaoudeh from UCI Health and Dr. Mustafa Al-Roubaie from Moffitt Cancer Center, whose expertise will guide RenovoRx's innovative drug delivery approach aimed at improving outcomes for patients with difficult-to-treat cancers.
See More
RenovoRx Announces New Clinical Data Presentation
- Clinical Data Presentation: RenovoRx will present new clinical data at the Society of Interventional Oncology Annual Meeting on February 6, 2026, focusing on real-time intravascular pressure measurements aimed at optimizing drug delivery in tumors, potentially enhancing treatment outcomes.
- Innovative Research Method: Led by Dr. Christopher Laing from Sutter Health, the study explores real-time intra-arterial pressure measurement methods using the adjustable double-balloon catheter within the TAMP therapy platform, demonstrating potential for optimizing targeted chemotherapy delivery.
- Reliability Validation: Findings indicate that an external pressure transducer provides reliable intra-arterial pressure measurements during TAMP procedures, showing strong correlation with intravascular pressure wire measurements in a porcine model, highlighting opportunities for procedural optimization.
- Clinical Application Prospects: Dr. Ramtin Agah, RenovoRx's Chief Medical Officer, emphasized that routine intra-arterial monitoring could enhance standardization and optimize delivery conditions, potentially improving clinical outcomes and advancing the commercialization of the TAMP therapy platform.
See More
RenovoRx Expands RenovoCath Adoption Across U.S. Cancer Centers
- Significant Commercial Progress: RenovoRx announced that 12 U.S. cancer centers are now utilizing the RenovoCath device, marking a substantial increase from previous figures and indicating strong market demand for the product.
- Growing Clinical Demand: With RenovoCath being integrated into overall cancer treatment paradigms, 33 centers have requested access to the device, tripling the number of centers since the first quarter, reflecting clinical recognition and demand.
- Sales Pipeline Expansion: RenovoRx's sales pipeline has significantly expanded since the first quarter of 2025, with the increase in potential commercial centers laying the groundwork for substantial revenue growth expected in 2026.
- Strategic Implications: The widespread adoption of RenovoCath not only enhances the company's market position in cancer treatment but also provides crucial support for future clinical research and product development, further solidifying its leadership in the industry.
See More
RenovoRx Expands Market for Cancer Treatment Device
- Market Demand Growth: Over the past year, the number of U.S. cancer centers utilizing RenovoRx's FDA-cleared device, RenovoCath, has increased to 12, indicating a rising clinical demand that is expected to drive revenue growth in 2026.
- Procedure Success Rate: Since receiving FDA clearance in 2014, RenovoCath has successfully completed over 700 procedures, reflecting strong physician satisfaction and an increase in repeat orders, further solidifying its market position.
- Executive Appointment Strengthens Strategy: The company appointed founder Dr. Ramtin Agah as Executive Chairman to leverage his medical background in driving market penetration and clinical adoption of RenovoCath, enhancing the execution of the company's commercial strategy.
- Sales Team Launch: RenovoRx's sales and marketing team, launched in late 2025, has begun promoting the adoption of the TAMP therapy platform, which is expected to further expand the customer base and increase market share.
See More
RenovoRx Clinical Data Abstract Accepted for Presentation at SIR 2026
- Clinical Data Abstract Accepted: RenovoRx announced that its clinical data abstract submitted for the 2026 Society of Interventional Radiology Annual Meeting has been accepted, showcasing the potential of its TAMP therapy platform for pancreatic cancer, which is expected to enhance the company's reputation in oncology treatment.
- Multidisciplinary Team Involvement: The abstract was submitted by a multidisciplinary team of experts from Moffitt Cancer Center, highlighting the involvement of Dr. Mustafa Al-Roubaie, a member of RenovoRx's Medical Advisory Board, indicating the company's influence and collaborative capabilities in the field.
- Innovative Treatment Mechanism: The abstract explores the hypothesis of local chemotherapy delivery via RenovoRx's patented TAMP platform to address the common issue of poor vascularity in pancreatic cancer patients, potentially improving treatment efficacy and offering new hope for patients.
- Future Outlook: The presentation of this abstract is scheduled for April 13, 2026, which is expected to attract industry attention, further driving RenovoRx's market promotion and product development, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Investor Focus: When considering buying Micron Technology (MU) stock, analysts' opinions are particularly crucial, and investors should pay attention to these rating changes to make informed investment choices.
- Source of Updates: Comprehensive information on analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a thorough market insight.
- Market Impact: Adjustments in analysts' ratings not only affect the performance of individual stocks but may also create fluctuations in overall market sentiment, prompting investors to closely monitor these changes to seize investment opportunities.
See More
RenovoRx Forms Medical Advisory Board to Enhance Oncology Strategies
- Formation of Medical Advisory Board: RenovoRx has established a dedicated Medical Advisory Board for RenovoCath, bringing together leading US interventional radiology experts to support clinical and strategic initiatives, thereby advancing the TAMP therapy platform in clinical indications with high unmet medical needs.
- Support for Clinical Trials: The MAB will provide critical insights into RenovoRx's clinical and market strategies, particularly in investigator-initiated trials supported by the company, which are designed to generate meaningful data that may broaden the application of the TAMP platform.
- Market Advancement of Product: With FDA clearance for the RenovoCath device, which enables targeted drug delivery across the arterial wall near tumors, the MAB's feedback will assist the sales and marketing team in bringing RenovoCath to market as a standalone device, enhancing its competitive position.
- Expert Team Composition: Initial members include experienced interventional radiologists such as Dr. Nadine Abi-Jaoudeh from UCI Health and Dr. Mustafa Al-Roubaie from Moffitt Cancer Center, whose expertise will guide RenovoRx's innovative drug delivery approach aimed at improving outcomes for patients with difficult-to-treat cancers.
See More
RenovoRx Announces New Clinical Data Presentation
- Clinical Data Presentation: RenovoRx will present new clinical data at the Society of Interventional Oncology Annual Meeting on February 6, 2026, focusing on real-time intravascular pressure measurements aimed at optimizing drug delivery in tumors, potentially enhancing treatment outcomes.
- Innovative Research Method: Led by Dr. Christopher Laing from Sutter Health, the study explores real-time intra-arterial pressure measurement methods using the adjustable double-balloon catheter within the TAMP therapy platform, demonstrating potential for optimizing targeted chemotherapy delivery.
- Reliability Validation: Findings indicate that an external pressure transducer provides reliable intra-arterial pressure measurements during TAMP procedures, showing strong correlation with intravascular pressure wire measurements in a porcine model, highlighting opportunities for procedural optimization.
- Clinical Application Prospects: Dr. Ramtin Agah, RenovoRx's Chief Medical Officer, emphasized that routine intra-arterial monitoring could enhance standardization and optimize delivery conditions, potentially improving clinical outcomes and advancing the commercialization of the TAMP therapy platform.
See More
